Subscribe to
our newsletters

Subscribe to our newsletters!

Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.

Search in Nordic Life Science Insight

-
September 17, 2019
Umeå Biotech Incubator

 Inficure Bio sets new record with major US deal

Umeå-based Inficure Bio signed the biggest deal in the company's history back in April. Now they have signed a new deal - which is twice as large.

 Inficure Bio sets new record with major US deal

Umeå-based Inficure Bio signed the biggest deal in the company's history back in April. Now they have signed a new deal - which is twice as large.

Umeå Biotech Incubator logotype

 

Sofia Mayans and Dan Holmberg, Inficure Bio

Sofia Mayans and Dan Holmberg, Inficure  Bio.

Umeå-based  Inficure Bio signed the biggest deal in the company's history back in April.  Now they have signed a new deal - which is twice as large.

“This is a  fantastic opportunity for us. Deals like this demonstrate that our  international credibility is increasing”, says Sofia Mayans, CEO of Inficure  Bio.

Inficure  Bio, formerly part of Umeå Biotech Incubator, has recently signed an  agreement with a publicly listed pharmaceutical manufacturer in the US. The  deal is twice as large as the previous record-breaking deal signed last  spring with a company in Switzerland.

“All  business deals are of course important, but the one we have signed now with  this US company really stands out. It is significantly larger than any deal  we have negotiated so far. It is also an indication that our impact on the  international pharmaceutical industry is increasing, says Sofia Mayans.

Inficure  Bio has developed a process that makes it easier and faster for  pharmaceutical companies to test drugs that treat fibrosis, which is scar  tissue in organs. Scar tissue occurs when the organ is damaged, and a common  cause of organ damage is inflammation of the tissue. While fibrosis in itself  may not be a serious health problem, uncontrolled fibrosis can result in  organ failure. An example of this is when the development of fatty liver  drives a constant inflammation that in turn leads to large amounts of  fibrosis and liver failure.

“The US  company is investing heavily in treatment of fibrosis and has many substances  under development. This deal gives us the opportunity to get long-term repeat  business as it is likely the company want to test more substances if the  tests we are currently conducting prove promising. Customers like this  provide us with stability and the opportunity to continue to develop”, says  Sofia Mayans.

“Our  focus has mainly been on the US, Europe and Australian markets but we are  currently also working on the introduction of our model into the Korean  market. This will certainly broaden our market opportunities and potential  revenues”, says Sofia Mayans.

For more  information:

Sofia  Mayans, PhD, CEO Inficure Bio
 +46 70-366 46 66
 sofia.mayans@inficurebio.com


About Inficure  Bio

InfiCure  Bio is a life science company focused on preclinical development and  validation of drugs that target chronic inflammatory and fibrotic conditions.

Based on  a panel of in vivo models for these conditions including a proprietary model  for chronic inflammation and fibrosis, we offer effect tests of  anti-inflammatory and anti-fibrotic drugs.

Founded  on extensive experience and expertise in immunology, inflammation and  fibrosis research, InfiCure Bio offers proficient and flexible processing of  drug validation projects in this area.

Umeå  Biotech Incubator (UBI) is one of Sweden’s state-of-the-art business  incubators within the life sciences. We help researchers to use their data to  the benefit of patients and citizens, improving their health. We support and  train entrepreneurs in the fields of pharmaceuticals, diagnostics and medical  engineering, and act as a bridge between academia, medicine and the business  community.

Last updated:
September 17, 2019

Umeå Biotech Incubator

Umeå Biotech Incubator is Sweden’s only life science incubator established by rebellious scientists. Today we have grown up to become a state of the art biotech incubator offering facilities, know-how and financing. We have been named one of Europe’s top 15 biotech incubators and we are aiming to become the best.

Click here to read more about us!
Get in touch with us!
Visit us
Send us mail

Umeå Biotech Incubator logotype

 

Sofia Mayans and Dan Holmberg, Inficure Bio

Sofia Mayans and Dan Holmberg, Inficure  Bio.

Umeå-based  Inficure Bio signed the biggest deal in the company's history back in April.  Now they have signed a new deal - which is twice as large.

“This is a  fantastic opportunity for us. Deals like this demonstrate that our  international credibility is increasing”, says Sofia Mayans, CEO of Inficure  Bio.

Inficure  Bio, formerly part of Umeå Biotech Incubator, has recently signed an  agreement with a publicly listed pharmaceutical manufacturer in the US. The  deal is twice as large as the previous record-breaking deal signed last  spring with a company in Switzerland.

“All  business deals are of course important, but the one we have signed now with  this US company really stands out. It is significantly larger than any deal  we have negotiated so far. It is also an indication that our impact on the  international pharmaceutical industry is increasing, says Sofia Mayans.

Inficure  Bio has developed a process that makes it easier and faster for  pharmaceutical companies to test drugs that treat fibrosis, which is scar  tissue in organs. Scar tissue occurs when the organ is damaged, and a common  cause of organ damage is inflammation of the tissue. While fibrosis in itself  may not be a serious health problem, uncontrolled fibrosis can result in  organ failure. An example of this is when the development of fatty liver  drives a constant inflammation that in turn leads to large amounts of  fibrosis and liver failure.

“The US  company is investing heavily in treatment of fibrosis and has many substances  under development. This deal gives us the opportunity to get long-term repeat  business as it is likely the company want to test more substances if the  tests we are currently conducting prove promising. Customers like this  provide us with stability and the opportunity to continue to develop”, says  Sofia Mayans.

“Our  focus has mainly been on the US, Europe and Australian markets but we are  currently also working on the introduction of our model into the Korean  market. This will certainly broaden our market opportunities and potential  revenues”, says Sofia Mayans.

For more  information:

Sofia  Mayans, PhD, CEO Inficure Bio
 +46 70-366 46 66
 sofia.mayans@inficurebio.com


About Inficure  Bio

InfiCure  Bio is a life science company focused on preclinical development and  validation of drugs that target chronic inflammatory and fibrotic conditions.

Based on  a panel of in vivo models for these conditions including a proprietary model  for chronic inflammation and fibrosis, we offer effect tests of  anti-inflammatory and anti-fibrotic drugs.

Founded  on extensive experience and expertise in immunology, inflammation and  fibrosis research, InfiCure Bio offers proficient and flexible processing of  drug validation projects in this area.

Umeå  Biotech Incubator (UBI) is one of Sweden’s state-of-the-art business  incubators within the life sciences. We help researchers to use their data to  the benefit of patients and citizens, improving their health. We support and  train entrepreneurs in the fields of pharmaceuticals, diagnostics and medical  engineering, and act as a bridge between academia, medicine and the business  community.

Last updated:
September 17, 2019

Umeå Biotech Incubator

Umeå Biotech Incubator is Sweden’s only life science incubator established by rebellious scientists. Today we have grown up to become a state of the art biotech incubator offering facilities, know-how and financing. We have been named one of Europe’s top 15 biotech incubators and we are aiming to become the best.

Click here to read more about us!
Get in touch with us!
Visit us
Send us mail